The Efficacy, Safety, and Economic Outcomes of Using Azithromycin in Respiratory Tract Infections: A Systematic Literature Review
Main Article Content
Abstract
Background: Azithromycin is widely used for the treatment of respiratory tract infections (RTIs) due to its broad-spectrum antibacterial activity and preferred safety profile. This study aimed to evaluate efficacy, safety, cost-effectiveness and societal benefits of azithromycin therapy in RTIs.
Methods: An extensive literature search was conducted following PRISMA guidelines. PubMed, Google scholar and Cochrane libraries database was searched for relevant studies published from 1990 to present. The population, intervention, comparator, outcomes, and study design (PICO) framework guided study selection criteria. Published literatures included randomized controlled trials (RCTs), observational studies, and economic evaluations assessing safety, efficacy, and cost outcomes of azithromycin therapy in respiratory tract infections, specifically upper respiratory tract infections. Data extraction and screening were performed by two independent researchers, with discrepancies resolved by a third researcher.
Results: Efficacy evaluation included systematic reviews and meta-analysis comparing azithromycin with other antibiotics. Azithromycin demonstrated superior clinical and comparable efficacy to alternative treatments. Safety analysis indicated that azithromycin had fewer adverse effects, although results varied across studies. Cost-effectiveness analysis revealed that azithromycin was consistently most cost-effective option, with lower direct and indirect costs compared to alternative treatments. Azithromycin's shorter treatment duration also led to reduced healthcare resource utilization, reduced sickness absenteeism, improvement in work and daily activities thereby mitigating overall societal costs.
Conclusion: Azithromycin exhibits a favorable risk-benefit profile in management of Upper RTIs, supported by its superior clinical efficacy, safety, and cost-effectiveness compared to alternative antimicrobials. Its shorter treatment duration contributes to reduced hospitalization periods and societal costs, making it a valuable therapeutic option for upper respiratory tract infections.
Limitations: Limited generalizability.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Alvear G, Santibáñez L, Sepúlveda R, Ramírez V, Martínez B. [Prescription of antibiotics in acute respiratory infections non-pneumonia in a private outpatient practice]. Rev Med Chil. 2022;150(8):10 00-1009. doi:10.4067/S0034-98872022000801000
3. Sandman Z, Iqbal OA. Azithromycin. In: StatPearls. StatPearls Publishing; 2024. Accessed March 4, 2024. http://www.ncbi.nlm.nih.gov/books/NBK557766/
4. Kong FYS, Rupasinghe TW, Simpson JA, et al. Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men. PLoS One. 2017;12(3):e0174372. doi:10.1371/journal.pone.0174372
5. Wenzel RP, Fowler AA. Clinical practice. Acute bronchitis. N Engl J Med. 2006;355(20):2125-2130. doi:10.1056/NEJMcp061493
6. Gyselinck I, Janssens W, Verhamme P, Vos R. Rationale for azithromycin in COVID-19: an overview of existing evidence. BMJ Open Respir Res. 2021 ;8(1):e000806. doi:10.1136/bmjresp-2020-000806
7. Klapan I, Culig J, Oresković K, Matrapazovski M, Radosević S. Azithromycin versus amoxicillin/ clavulanate in the treatment of acute sinusitis. Am J Otolaryngol. 1999;20(1):7-11. doi:10.1016/s0196 -0709(99)90044-3
8. Henry DC, Riffer E, Sokol WN, Chaudry NI, Swanson RN. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother. 2003;47(9):2770-2774. doi:10. 1128/AAC.47.9.2770-2774.2003
9. Davidson RJ.
In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections
. IDR. 2019;12:585-596. doi:10.2147/IDR.S18722610. Li P, Jiang G, Shen X. Evaluation of 3-day azithromycin or 5-day cefaclor in comparison with 10-day amoxicillin for treatment of tonsillitis in children. Can J Physiol Pharmacol. 2019;97(10):939 -944. doi:10.1139/cjpp-2019-0087
11. Dawit G, Mequanent S, Makonnen E. Efficacy and safety of azithromycin and amoxicillin/ clavulanate for otitis media in children: a systematic review and meta-analysis of randomized controlled trials. Annals of Clinical Microbiology and Antimicrobials. 2021;20(1):28. doi:10.1186/s12941-021-00434-x
12. El Hennawi DED, Geneid A, Zaher S, Ahmed MR. Management of recurrent tonsillitis in children. Am J Otolaryngol. 2017;38(4):371-374. doi:10.101 6/j.amjoto.2017.03.001
13. Amali A, Saedi B, Rahavi-Ezabadi S, Ghazavi H, Hassanpoor N. Long-term postoperative azithromycin in patients with chronic rhinosinusitis: A randomized clinical trial. Am J Rhinol Allergy. 2015;29(6):421-424. doi:10.2500/ajra.2015.29.4244
14. Donde S, Mishra A, Kochhar P. Azithromycin in Acute Bacterial Upper Respiratory Tract Infections: An Indian Non-Interventional Study. Indian J Otolaryngol Head Neck Surg. 2014;66(Suppl 1):225-230. doi:10.1007/s12070-011-0437-x
15. Lakoš AK, Pangerčić A, Gašparić M, Kukuruzović MM, Kovačić D, Baršić B. Safety and effectiveness of azithromycin in the treatment of respiratory infections in children. Current Medical Research and Opinion. 2012;28(1):155-162. doi:10. 1185/03007995.2011.639355
16. Gulani A, Sachdev HPS, Qazi SA. Efficacy of short course (<4 days) of antibiotics for treatment of acute otitis media in children: A systematic review of randomized controlled trials. Indian Pediatr. 2010;47(1):74-87. doi:10.1007/s13312-010-0010-9
17. Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev. 2005;(1):CD004404. doi:10.1002/14651858.CD004404.pub2
18. Murray JJ, Emparanza P, Lesinskas E, Tawadrous M, Breen JD. Efficacy and Safety of a Novel, Single‐dose Azithromycin Microsphere Formulation Versus 10 Days of Levofloxacin for the Treatment of Acute Bacterial Sinusitis in Adults. Otolaryngol--head neck surg. 2005;133(2):194-200. doi:10.1016/j.otohns.2005.04.020
19. Oğuz F, Ünüvar E, Süoğlu Y, et al. Etiology of acute otitis media in childhood and evaluation of two different protocols of antibiotic therapy: 10 days cefaclor vs. 3 days azitromycin. International Journal of Pediatric Otorhinolaryngology. 2003;67( 1):43-51. doi:10.1016/S0165-5876(02)00360-9
20. Lildholdt T, Doessing H, Lyster M, Outzen KE. The natural history of recurrent acute tonsillitis and a clinical trial of azithromycin for antibiotic prophylaxis. Clin Otolaryngol. 2003;28(4):371-373. doi:10.1046/j.1365-2273.2003.00728.x
21. Ioannidis JPA. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. Journal of Antimicrobial Chemotherapy. 2001;48(5):677-689. doi:10.1093/jac/48.5.677
22. Guay DRP. Short-course antimicrobial therapy for upper respiratory tract infections. Clinical Therapeutics. 2000;22(6):673-684. doi:10.1016/S0 149-2918(00)90003-1
23. Müller O. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother. 1993;31 Suppl E:137-146. doi:10.1093 /jac/31.suppl_e.137
24. Aldhahri RK, Gabb SG, Shoaib OA, Almadani RM, Eljaaly K, Thabit AK. Doxycycline vs. macrolides in combination with a β-lactam antibiotic for the treatment of community-acquired pneumonia in inpatients. Eur J Med Res. 2022; 27(1):279. doi:10.1186/s40001-022-00912-8
25. Al-Salloum J, Gillani SW, Mahmood RK, Gulam SM. Comparative efficacy of azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review. J Int Med Res. 2021;49(10):030006052110499. doi:10.1177/03000605211049943
26. Kawamura K, Ichikado K, Suga M, Yoshioka M. Efficacy of Azithromycin for Treatment of Acute Exacerbation of Chronic Fibrosing Interstitial Pneumonia: A Prospective, Open-Label Study with Historical Controls. Respiration. 2014;87(6):478-484. doi:10.1159/000358443
27. Beigelman A, Isaacson-Schmid M, Sajol G, et al. Randomized trial to evaluate azithromycin’s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2015;135(5):1171-1178.e1. doi:10.1016/j.jaci.2014.10.001
28. Smith C, Egunsola O, Choonara I, Kotecha S, Jacqz-Aigrain E, Sammons H. Use and safety of azithromycin in neonates: a systematic review. BMJ Open. 2015;5(12):e008194. doi:10.1136/bmjopen-2015-008194
29. D’Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD. Novel, Single-Dose Microsphere Formulation of Azithromycin versus 7-Day Levofloxacin Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults. Antimicrob Agents Chemother. 2005;49(10):4035-4041. doi:10.1128/AAC.49.10.4035-4041.2005
30. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698. doi:10 .1056/NEJMoa1104623
31. Sun Y wen, Cen Y hua, Chen M heng, Yan X ke, Jin X fen. Safety profiles and adverse reactions of azithromycin in the treatment of pediatric respiratory diseases: A systematic review and meta-analysis. Medicine. 2023;102(48):e36306. doi:10.1097/MD.0000000000036306
32. Parmar D, Jadav S, Shah B. Can azithromycin be substituted for amoxycillin in upper respiratory tract infections? An observation based on a drug utilization at some primary health centers. Indian J Pharmacol. 2007;39(1):55. doi:10.4103/0253-7613.30766
33. EFFECTIVENESS AND COST-EFFECTIVENESS OF ANTIBIOTIC TREATMENTS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP) AND ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) | Journal of Population Therapeutics and Clinical Pharmacology. Accessed March 7, 2024. https://www.jptcp.com/index.php/jptcp/article/view/90
34. Samsa GP, Matchar DB, Harnett J, Wilson J. A Cost-Minimization Analysis Comparing Azithromycin-Based and Levofloxacin-Based Protocols for the Treatment of Patients Hospitalized With Community-Acquired Pneumonia. Chest. 2005;128(5):3246-3254. doi:10.1378/chest.128.5.3246
35. Rahav G, Fidel J, Gibor Y, Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int J Antimicrob Agents. 2004;24(2):181-184. doi:10.10 16/j.ijantimicag.2004.01.011
36. McCarty JM. Azithromycin (Zithromax(R)).
37. Morimoto T, Koyama H, Shimbo T, Fukui T. [Cost-effectiveness analysis of ambulatory treatment for adult patients with community-acquired pneumonia: according to Japanese Respiratory Society guidelines]. Nihon Kokyuki Gakkai Zasshi. 2002;40(1):17-25.
38. Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin | Journal of Antimicrobial Chemotherapy | Oxford Academic. Accessed March 7, 2024. https://academic.oup.com/jac/article/37/suppl_C/151/683595?login=false
39. Azithromycin Compared with Clarithromycin in the Treatment of Adult Patients with Acute Purulent Tracheobronchitis: A Cost of Illness Study - J Sternon, , Bruxelles the Collaborative Group of the Centre Universitaire de Medécine Générale de l’ Université Libre, Bruxelles the Collaborative Group of the Centre Universitaire de Medécine Générale de l’ Université Libre, P Leclerq, C Knepper, K Blot, 1995. Accessed March 7, 2024. https://journals.sagepub.com/doi/abs/10.1177/030006059502300602
40. Mahashur A. Management of lower respiratory tract infection in outpatient settings: Focus on clarithromycin. Lung India. 2018;35(2):143-149. doi:10.4103/lungindia.lungindia_262_17
41. Azithromycin - an overview | ScienceDirect Topics. Accessed April 29, 2024. https://www.sciencedirect.com/topics/chemistry/azithromycin
42. Treadway G, Pontani D, Reisman A. The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections. Int J Antimicrob Agents. 2002;19(3):189-194. doi:10. 1016/s0924-8579(01)00490-3